Rafferty Asset Management
DRNA

Rafferty Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Rafferty Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-143,589
Closed -$2.9M – 1349
2021
Q3 		$2.9M Buy
143,589
+73,769
+106% +$2.04M 0.02% 498
2021
Q2 		$2.61M Sell
69,820
-50,037
-42% -$1.53M 0.02% 578
2021
Q1 		$3.06M Buy
119,857
+97,384
+433% +$2.49M 0.02% 477
2020
Q4 		$495K Sell
22,473
-51,689
-70% -$1.14M ﹤0.01% 688
2020
Q3 		$1.33M Buy
74,162
+46,611
+169% +$965K 0.02% 527
2020
Q2 		$700K Buy
+27,551
New +$594K 0.01% 630
2020
Q1 		– Sell
-29,364
Closed -$647K – 861
2019
Q4 		$647K Sell
29,364
-43,882
-60% -$883K 0.01% 649
2019
Q3 		$1.05M Buy
73,246
+9,323
+15% +$133K 0.02% 526
2019
Q2 		$1.01M Buy
63,923
+681
+1% +$9.26K 0.02% 562
2019
Q1 		$926K Buy
+63,242
New +$727K 0.01% 563

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Rafferty Asset Management's DRNA Position: Q4 2021 in Review

Rafferty Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 143,589 shares — an estimated $2.9M sold.

Rafferty Asset Management first reported a position in DRNA in Q1 2019 and held it in 10 quarters. The position peaked at $3.06M in Q1 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Rafferty Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 143,589 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $2.9M.
  • Rafferty Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 10 quarters.
  • Rafferty Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $3.06M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.